MedPath

Tagged News

AI-Guided Discovery of Enterololin Offers New Hope for IBD Treatment

AIDrug Discovery
  • Researchers at McMaster University and MIT have discovered enterololin, a narrow-spectrum antibiotic that specifically targets disease-causing bacteria in inflammatory bowel diseases while preserving beneficial gut microbiome.
  • The breakthrough utilized AI to predict the drug's mechanism of action in just six months for $60,000, compared to traditional methods that typically require two years and $2 million.
  • Enterololin targets the Enterobacteriaceae family including E. coli strains that drive Crohn's disease, offering a promising treatment option for millions of IBD patients who currently have no cure.
  • Stoked Bio has licensed the drug and aims to begin human trials within three years, with early results showing promise against other drug-resistant bacteria like Klebsiella.

Major Pharma Companies Form AI Consortium to Accelerate Drug Discovery Through Federated Data Sharing

AIDrug Discovery
  • Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.
  • The companies will contribute data from several thousand experimentally determined protein-small molecule structures using a federated sharing model that keeps sensitive data secure.
  • The initiative aims to improve OpenFold3's accuracy in predicting protein-small molecule interactions, enabling advances in small molecule discovery beyond what individual companies could achieve alone.
  • OpenFold3 represents the flagship project of the industry-led AI Structural Biology Network, developed in collaboration with Columbia University's AlQuraishi Lab.

Lunai Bioworks Completes Corporate Rebranding with Focus on AI-Powered Drug Discovery and Parkinson's Research

AIDrug Discovery
  • Lunai Bioworks Inc. (formerly Renovaro Inc.) officially adopted its new corporate identity on September 30, 2025, trading under ticker symbol "LNAI" following a 10:1 reverse stock split.
  • The company launched a proprietary transformer-based platform that embeds neurotoxicity intelligence into generative AI pipelines for safe compound discovery and biodefense applications.
  • Through subsidiary BioSymetrics Inc., Lunai advanced a preclinical biomarker discovery program in Parkinson's Disease using phenogrouping and multimodal data analysis.
  • BioSymetrics secured a multi-year STTR grant from NIH to support platform expansion and validation of their AI-driven therapeutic discovery capabilities.

BenchSci Partners with Thermo Fisher Scientific to Deploy AI-Powered Drug Discovery Tools

AIDrug Discovery
  • BenchSci announced a strategic partnership with Thermo Fisher Scientific to develop AI-powered research tools that accelerate experimental design and improve R&D productivity for life sciences researchers.
  • The collaboration will leverage BenchSci's ASCEND™ AI technology to create enterprise software solutions for scientific instruments, advanced literature search capabilities, and optimized reagent selection tools.
  • The partnership enables clients to use BenchSci's software to design experiments with Thermo Fisher equipment, analyze results, and feed data back into the system to guide future discoveries.
  • BenchSci's AI platform compiles data from academic publications, patent filings, clinical trials, and pharmaceutical clients' experiments, accessible through an AI chatbot interface for scientific inquiries.

Recursion Pharmaceuticals Advances AI-Powered Cancer Drug REC-617 to Phase 2 Trial Despite High-Risk Profile

AIDrug Discovery
  • Recursion Pharmaceuticals has advanced its lead cancer drug candidate REC-617, a novel CDK7 inhibitor, to phase 2 clinical trials with top-line results expected in 2028.
  • The company is applying artificial intelligence to drug discovery processes, with analysts projecting a potential 53% stock price increase despite the inherent risks of biotech development.
  • REC-617 could become the first cancer treatment of its kind if successful, though the majority of cancer drugs advancing from phase 1 to phase 2 trials never earn approval or generate sales.

Illumina Launches BioInsight AI Unit and Expands KRAS Companion Diagnostic Partnerships

AIDrug Discovery
  • Illumina launched BioInsight, a new AI-driven business unit focused on multiomic data analysis for drug discovery, with Rami Mehio as senior vice president and general manager.
  • The company secured multiple global pharmaceutical partnerships to advance its TruSight Oncology genomic profiling assay as a companion diagnostic targeting KRAS alterations.
  • This strategic shift represents Illumina's transition from sequencing hardware toward comprehensive AI-powered data analysis and deeper pharmaceutical collaborations.
  • Despite recent partnerships, the company faces ongoing challenges from U.S. research funding uncertainty and competitive pressures in the genomics market.

Concept Life Sciences Establishes One of UK's Largest Drug Discovery Research Sites with Major Facility Expansion

Drug Discovery
  • Concept Life Sciences officially opened its expanded integrated drug discovery facilities at Chapel-en-le-Frith, bringing chemistry, ADMET and screening biology capabilities together under one roof with 130 scientists on site.
  • The expansion establishes one of the UK's largest drug discovery research sites and is expected to provide high-value life sciences job opportunities in the Manchester and Sheffield region.
  • The company has successfully helped 29 drug candidates advance to the clinic and can accelerate drug development from concept to clinic in as little as 32 months, well ahead of the industry average of 60 months.
  • The state-of-the-art facilities offer custom-fit drug discovery solutions across multiple modalities including small molecules, biologics, peptides, and cell & gene therapies.

N2OFF Stockholders Approve Acquisition of MitoCareX Bio, Targeting Mitochondrial SLC25 Proteins for Cancer Therapy

Drug Discovery
  • N2OFF stockholders approved the acquisition of MitoCareX Bio, a biotech company developing novel therapies for hard-to-treat cancers by targeting the mitochondrial SLC25 protein family.
  • MitoCareX utilizes 3D comparative modeling and advanced in-vitro screening systems to identify anti-cancer small molecule therapeutics through its computational platform.
  • The transaction involves N2OFF purchasing shares for $700,000 and exchanging additional shares totaling 40% of the company's fully diluted capital stock, with closing expected in the first half of October 2025.
  • The global cancer therapeutics and biotherapeutics market was valued at $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031.

Lunai Bioworks Advances AI-Powered Parkinson's Biomarker Discovery Program for Strategic Pharma Partnerships

AIPrecision MedicineDrug Discovery
  • Lunai Bioworks has advanced its preclinical biomarker discovery program for Parkinson's Disease using its subsidiary BioSymetrics' proprietary Augusta Platform, positioning the initiative for strategic pharmaceutical partnerships.
  • The program leverages phenogrouping technology to identify distinct patient subtypes with greater precision, enabling targeted therapeutic development in a market affecting over 10 million people globally.
  • The company's approach has received validation through a competitive STTR grant from the National Institutes of Health and recognition from the Michael J. Fox Foundation.
  • With Parkinson's incidence expected to double by 2050, the expanding patient population represents a significant unmet medical need and compelling opportunity for therapeutic innovation.

Prellis Biologics Partners with Eli Lilly to Accelerate Antibody Discovery Using Novel Biological AI Platform

AIMonoclonal AntibodyDrug Discovery
  • Prellis Biologics announced a multi-target drug discovery collaboration with Eli Lilly combining Prellis' EXIS™ organoid platform with Lilly's development expertise.
  • The partnership leverages Prellis' proprietary lymph node organoid technology that generates diverse, high-affinity antibodies in 3-4 weeks using fully human artificial immune systems.
  • Prellis' biological AI platform represents the first system to design drugs by combining living human lymph node organoids with generative AI refinements.
  • The collaboration aims to accelerate discovery of fully human antibodies for multiple disease targets including GPCRs with enhanced therapeutic efficacy and manufacturability.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.